Session Information
-
WCLC 2017
18th World Conference on Lung Cancer
Conference Program for the 18th World Conference on Lung Cancer in Yokohama, Japan
Download PDF of the Conference Program: Click Here.
Onsite Conference Program Addendum (17/10/2017): Click Here.
Download PDF of the Abstract Book: Click Here.
Financial Disclosure Summary (PDF): Click Here.Presentation Date(s):- Oct 15 - 18, 2017
- Total Presentations: 2295
October 14 Sat
Oct 14 Sunday
October 15 Sun
Oct 15 Monday
October 16 Mon
Oct 16 Tuesday
October 17 Tue
Oct 17 Wednesday
October 18 Wed
Oct 18
-
+
P1.01 - Advanced NSCLC
- 09:30 - 16:00
- 10/16/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
-
+
P1.01-052 - Patient-Reported Outcomes (PROs) in OAK: A Phase III Study of Atezolizumab vs Docetaxel in Non-Small-Cell Lung Cancer (NSCLC)
09:30 - 09:30 | Presenter: M. Ballinger | Author(s): Rodolfo Bordoni, F. Ciardiello, J. Von Pawel, D. Cortinovis, P. He, T. Karagiannis, A. Sandler, W. Yu, F. Felizzi, A. Rittmeyer
- Abstract
Loading...
-
+
P1.15 - SCLC/Neuroendocrine Tumors
- 09:30 - 16:00
- 10/16/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: SCLC/Neuroendocrine Tumors
-
+
P1.15-004 - An Open-Label, Multitumor Phase II Basket Study of Olaparib and Durvalumab (MEDIOLA): Results in Patients with Relapsed SCLC
09:30 - 09:30 | Presenter: Matthew G Krebs | Author(s): K. Ross, Sang-We Kim, M. De Jonge, Fabrice Barlesi, S. Postel-Vinay, S.M. Domchek, J. Lee, H.K. Angell, K. Bui, S. Chang, C. Gresty, P. Herbolsheimer, J. Delord
- Abstract
Loading...
-
+
MA 05 - Immuno-Oncology: Novel Biomarker Candidates
- 15:45 - 17:30
- 10/16/2017
- Location: Room 303 + 304
- Type: Mini Oral
- Track: Immunology and Immunotherapy
- Moderators:Yoichi Nakanishi, P. Mitchell
-
+
MA 05.09 - Pre-Existing Immunity Measured by Teff Gene Expression in Tumor Tissue is Associated with Atezolizumad Efficacy in NSCLC
16:35 - 16:40 | Presenter: Marcin Kowanetz | Author(s): W. Zou, M. McCleland, David R. Gandara, Shirish M Gadgeel, A. Rittmeyer, Fabrice Barlesi, Keunchil Park, D.S. Shames, H. Koeppen, M. Ballinger, A. Sandler, P. Hegde
- Abstract
Loading...
-
+
MA 10 - Immunotherapy I
- 11:00 - 12:30
- 10/17/2017
- Location: Room 303 + 304
- Type: Mini Oral
- Track: Immunology and Immunotherapy
- Moderators:S. Wang, Robert Pirker
-
+
MA 10.03 - 3-Year Survival and Duration of Response in Randomized Phase II Study of Atezolizumab vs Docetaxel in 2L/3L NSCLC (POPLAR)
11:10 - 11:15 | Presenter: Keunchil Park | Author(s): C. Lewanski, Shirish M Gadgeel, L. Fehrenbacher, Julien Mazieres, A. Rittmeyer, Ji-Youn Han, A. Artal-Cortes, F. Braiteh, M. Gandhi, W. Yu, C. Matheny, P. He, A. Sandler, M. Ballinger, Johan F. Vansteenkiste
- Abstract
Loading...
-
+
P3.01 - Advanced NSCLC
- 09:30 - 16:00
- 10/18/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
-
+
P3.01-017 - Clinical Outcomes of Patients with EGFR T790M + NSCLC on Osimertinib
09:30 - 09:30 | Presenter: Wan Ling Tan | Author(s): T.P. Hennedige, Q.S. Ng, S.H. Tan, N.T.A. Tran, B.J.G. Chua, C.K. Toh, E.H. Tan, Daniel SW Tan, M. Ang, R. Kanesvaran, A. Jain, T.K.H. Lim, A. Gogna, M. Koh, C.S.P. Yip, C.H. Thng, B. Chowbay, M.H. Tan, Wan-Teck Lim
- Abstract
Loading...
-
+
OA 17 - Immunotherapy II
- 14:30 - 16:15
- 10/18/2017
- Location: Room 301 + 302
- Type: Oral
- Track: Immunology and Immunotherapy
- Moderators:Yuichiro Ohe, Anne Tsao
-
+
OA 17.07 - Long-Term Survival in Atezolizumab-Treated Patients with 2L+ NSCLC from Ph III Randomized OAK Study
15:35 - 15:45 | Presenter: Miyako Satouchi | Author(s): L. Fehrenbacher, Manuel Cobo Dols, Ji-Youn Han, J. Von Pawel, R. Bordoni, T. Hida, Keunchil Park, D. Moro-Sibilot, P. Conkling, C. Matheny, W. Yu, P. He, Marcin Kowanetz, M. Gandhi, M. Ballinger, A. Sandler, David R. Gandara
- Abstract
Loading...